Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon.

Objectives: Prolonged lamivudine treatment in adults has been shown to improve hepatitis B e (HBe) seroconversion rates in patients with chronic hepatitis B. This prospective open study reports the results of prolonged lamivudine treatment in a group of children with chronic hepatitis B.

Patients And Methods: Twenty-two children and adolescents age 13.

The effect of early treatment in children with chronic hepatitis.

Background: The aim of this study was to compare the efficacy of interferon alpha (IFN) or IFN and ribavirin (IFN+RIB) combination therapy in children with chronic hepatitis C (CHC). Most children were infected during treatment for pediatric malignancies.

Patients And Methods: We reviewed the charts of 20 patients (11 boys and 9 girls) aged 10.

Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.

Background/aims: Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication. This prospective open study reports the results of lamivudine treatment in children with chronic hepatitis B infection who did not respond to previous interferon treatment.

Patients And Methods: Lamivudine, 3 mg/kg/day (maximum, 100 mg/day), was given for 52 weeks to 20 children and adolescents, ages 8.

Interferon treatment in children with chronic hepatitis B: an Israeli experience.

Objective: To summarize the experience of two pediatric gastroenterology centers in northern Israel using interferon alpha to treat children with chronic hepatitis B.

Patients And Methods: We retrospectively reviewed the medical records of 59 children with chronic HBV. Forty-nine children were treated with subcutaneous IFN alpha at dosages of 10 MU/m (n = 12) or 5 MU/m (n = 37) three times a week for 6 months.